Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 9Uterine Cervical Neoplasms 7Colonic Neoplasms 6Breast Neoplasms 5Uterine Cervical Dysplasia 4Urinary Bladder Neoplasms 4Papillomavirus Infections 3Neuroblastoma 3Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Brain Neoplasms 3Anus Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Intraepithelial Lesions 2Rectal Neoplasms 2Precancerous Conditions 2Oropharyngeal Neoplasms 2Neoplasms 2Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2HIV Infections 2

Interventions

Gemcitabine 30Mitomycin 25BCG Vaccine 11Docetaxel 10Epirubicin 6erdafitinib 5durvalumab 5Radiotherapy 5dodecyl maltoside 4apaziquone 4tislelizumab 3Cystoscopy 3ALT-803 3viscum album peptide 2pembrolizumab 2disitamab vedotin 2avelumab 2VB4-845 2Therapeutics 2Imiquimod 2Hyaluronic Acid 25-aminolevulinic acid hexyl ester 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1monalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non-Muscle Invasive Bladder Neoplasms × Watchful Waiting × Clear all
NCT07625527 2026-06-04

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

Tianjin Medical University Second Hospital

Phase 2 Not yet recruiting
120 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡